Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:37 pm Sale | 2024-09-30 | 13G | Spero Therapeutics, Inc. SPRO | Anson Funds Management LP | 3,750,450 6.900% | -547,149 (-12.73%) | Filing History |
| 2024-02-14 4:25 pm Purchase | 2023-12-31 | 13G | Spero Therapeutics, Inc. SPRO | Anson Funds Management LP | 4,297,599 8.100% | 4,297,599 (New Position) | Filing History |
| 2023-02-14 11:47 am Sale | 2022-12-31 | 13G | Spero Therapeutics, Inc. SPRO | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -3,411,520 (Position Closed) | Filing History |
| 2023-02-14 11:16 am Sale | 2022-12-31 | 13G | Spero Therapeutics, Inc. SPRO | Aquilo Capital Management LLC | 0 0.000% | -3,419,435 (Position Closed) | Filing History |
| 2023-01-20 4:08 pm Unchanged | 2022-11-14 | 13D | Spero Therapeutics, Inc. SPRO | GSK plc | 9,190,606 17.750% | 0 (Unchanged) | Filing History |
| 2022-11-14 5:02 pm Purchase | 2022-11-07 | 13D | Spero Therapeutics, Inc. SPRO | GSK plc | 9,190,606 19.990% | 7,450,000 (+428.01%) | Filing History |
| 2022-10-03 4:40 pm Sale | 2022-09-22 | 13G | Spero Therapeutics, Inc. SPRO | Aquilo Capital Management LLC | 3,419,435 9.800% | -1,602,101 (-31.90%) | Filing History |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Spero Therapeutics, Inc. SPRO | BlackRock Inc. BLK | 690,753 2.100% | -1,108,024 (-61.60%) | Filing History |
| 2022-03-08 5:41 pm Purchase | 2022-01-18 | 13G | Spero Therapeutics, Inc. SPRO | Aquilo Capital Management LLC | 5,021,536 15.500% | 57,355 (+1.16%) | Filing History |
| 2022-02-14 3:54 pm Purchase | 2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO | Aquilo Capital Management LLC | 4,964,181 15.400% | 1,031,972 (+26.24%) | Filing History |
| 2022-02-14 1:27 pm Purchase | 2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO | BIOTECHNOLOGY VALUE FUND L P | 3,411,520 9.990% | 643,242 (+23.24%) | Filing History |
| 2022-02-03 4:29 pm Purchase | 2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO | BlackRock Inc. BLK | 1,798,777 5.600% | 67,177 (+3.88%) | Filing History |
| 2022-01-25 11:28 am Unchanged | 2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO | Atlas Venture Fund IX L.P. | 1,376,968 4.260% | 0 (Unchanged) | Filing History |
| 2021-09-16 5:27 pm Unchanged | 2021-08-05 | 13D | Spero Therapeutics, Inc. SPRO | GSK plc | 1,740,606 5.400% | 0 (Unchanged) | Filing History |
| 2021-07-09 4:25 pm Purchase | 2021-06-30 | 13G | Spero Therapeutics, Inc. SPRO | PFIZER INC PFE | 2,362,348 7.370% | 2,362,348 (New Position) | Filing History |
| 2021-02-16 5:29 pm Unchanged | 2021-02-12 | 13D | Spero Therapeutics, Inc. SPRO | Atlas Venture Fund X L.P. | 1,031,160 3.800% | 0 (Unchanged) | Filing History |
| 2021-02-16 4:00 pm Sale | 2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO | Aquilo Capital Management LLC | 3,932,209 14.500% | -564,933 (-12.56%) | Filing History |
| 2021-02-12 8:16 pm Purchase | 2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO | BIOTECHNOLOGY VALUE FUND L P | 2,768,278 9.990% | 739,873 (+36.48%) | Filing History |
| 2021-02-10 4:37 pm Sale | 2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO | GV 2015 L.P. | 889,979 3.270% | -222,494 (-20.00%) | Filing History |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO | BlackRock Inc. BLK | 1,731,600 6.400% | 1,731,600 (New Position) | Filing History |